[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6336]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3285. Mrs. BLACKBURN submitted an amendment intended to be 
proposed by her to the concurrent resolution S. Con. Res. 14, setting 
forth the congressional budget for the United States Government for 
fiscal year 2022 and setting forth the appropriate budgetary levels for 
fiscal years 2023 through 2031; which was ordered to lie on the table; 
as follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO RELATING 
                   TO SUPPORTING THE ADVANCEMENT, DEVELOPMENT, AND 
                   IMPLEMENTATION OF ADVANCED AND CONTINUOUS 
                   PHARMACEUTICAL MANUFACTURING.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     relating to supporting the advancement, development, and 
     implementation of advanced and continuous pharmaceutical 
     manufacturing, which may include designating national centers 
     of excellence, by the amounts provided in such legislation 
     for those purposes, provided that such legislation would not 
     increase the deficit over either the period of the total of 
     fiscal years 2022 through 2026 or the period of the total of 
     fiscal years 2022 through 2031.
                                 ______